GSK plc vs JPMorgan Equity Premium Income ETF — how do they compare? GSK plc trades at $50.37 (market cap $102.60B), while JPMorgan Equity Premium Income ETF trades at $57.85. The key difference: GSK plc pays a 3.57% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals.
| GSK | JEPI | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $59.88 |
52-Week Low | $38.96 | $55.29 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
JEPI trades at $57.84, up 0.35% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent dividends of $0.39 and $0.37 highlight its income focus, while news coverage emphasizes its role in retirement portfolios amid competitive yield pressures from peers like SPYI and JEPQ.
The outlook is mixed: strong income appeal supports demand, but underperformance versus covered-call peers and tax inefficiencies risk long-term returns. Investors face trade-offs between monthly distributions and capital appreciation, with sentiment divided on whether JEPI's strategy justifies opportunity costs.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →